switching between semaglutide and tirzepatide from to Tirzepatide: Is It Safe? A Comprehensive Guide for Smooth

Exenatide maintained glycemic control with associated weight reduction over 2 years in patients with type 2 diabetes

Its associated with modest weight loss

Median follow up was 8.8 years, during which Lhteenvuo and colleagues found that 133,210 individuals (58.5%) were hospitalized for AUD at least once, and 138,390 individuals were hospitalized for any SUD

Treatment duration typically runs six to twelve weeks

It is important to follow prescribed dosing, preparation, and administration instructions to help reduce the risk of complications

10.1111/dom.14990 Summary Keywords cardiovascular disease, major adverse cardiovascular events, semaglutide, type 2 diabetes mellitus, meta-analysis Citation Tan S, Yin Y and Lu J (2025) Effects of subcutaneous or oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials